Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL/SLL who have previously been treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or were refractory to such therapy or discontinued such therapy due to toxicity.
Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma
DRUG: Duvelisib
Overall Response Rate (ORR), From start of treatment to first documented response, 2 cycles (58 days)
Treatment-Emergent adverse events (TEAEs) and changes in laboratory values, From start of treatment to end of treatment plus 30 days; 7 months|Duration of response (DOR), defined as the time from the first documentation of response to the first documentation of PD or death due to any cause, Time from the first documentation of response to first documentation of progressive disease or death due to any cause, 6 months|Progression-free survival (PFS), defined as the time from the first dose of study treatment to the first documentation of PD or death from any cause, Time from start of treatment to first documentation of progression or date of death from any cause, whichever came first, 4 months|Disease control rate (DCR), defined as CR/CRi + PR/PRwL + stable disease (SD) ≥ 8 weeks, Greater than or equal to 8 weeks
This is a multi-center, single-arm, open-label, Phase 2 study of duvelisib, an orally bioavailable dual inhibitor of PI3K-δ,γ, in patients with CLL/SLL who have previously been treated with ibrutinib or another Bruton's Tyrosine Kinase Inhibitor (BTKi) and relapsed or were refractory to such therapy or discontinued such therapy due to toxicity.